InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Oregon Health and Science University
May 08 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp.
(NVIV) today announced that a new patient has been
enrolled into The INSPIRE Study (InVivo Study of
Probable Benefit of the Neuro-Spinal Scaffold™ for Safety
and Neurologic Recovery in Subjects with Complete Thoracic
AIS A Spinal Cord Injury) at Oregon Health & Science University
(OHSU) in Portland, Oregon. Jason J. Chang, M.D., Assistant
Professor of Neurological Surgery and co-study investigator,
performed the surgery and implantation approximately 77 hours after
the injury occurred.
Mark Perrin, InVivo’s Chief Executive Officer
and Chairman, said, “We were pleased to hear that the procedure was
a success and that the patient is doing well. We now have 15
patients enrolled and in follow up, and we look forward to
completing enrollment in the INSPIRE study.”
For more information on the INSPIRE study,
please visit the company’s ClinicalTrials.gov registration site:
http://clinicaltrials.gov/ct2/show/study/NCT02138110
About the Neuro-Spinal Scaffold™
Implant
Following acute spinal cord injury, surgical
implantation of the biodegradable Neuro-Spinal Scaffold within the
decompressed and debrided injury epicenter is intended to support
appositional healing, thereby reducing post-traumatic cavity
formation, sparing white matter, and allowing neural regeneration
across the healed wound epicenter. The Neuro-Spinal Scaffold, an
investigational device, has received a Humanitarian Use Device
(HUD) designation and currently is being evaluated in The INSPIRE
Study for the treatment of patients with acute, complete (AIS A),
thoracic traumatic spinal cord injury and a pilot study for acute,
complete (AIS A), cervical (C5-T1) traumatic spinal cord injury.
For more information on the cervical study, refer to
https://clinicaltrials.gov/ct2/show/study/NCT03105882.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a
research and clinical-stage biomaterials and biotechnology company
with a focus on treatment of spinal cord injuries. The company was
founded in 2005 with proprietary technology co-invented by Robert
Langer, Sc.D., Professor at Massachusetts Institute of Technology,
and Joseph P. Vacanti, M.D., who then was at Boston Children’s
Hospital and who now is affiliated with Massachusetts General
Hospital. In 2011, the company earned the David S. Apple Award from
the American Spinal Injury Association for its outstanding
contribution to spinal cord injury medicine. In 2015, the company’s
investigational Neuro-Spinal Scaffold received the 2015 Becker’s
Healthcare Spine Device Award. The publicly-traded company is
headquartered in Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements within the meaning of the federal
securities laws. These statements can be identified by words such
as "believe," "anticipate," "intend," "estimate," "will," "may,"
"should," "expect," “designed to,” “potentially,” and similar
expressions, and include statements regarding the safety and
effectiveness of the Neuro-Spinal Scaffold and the progress of the
clinical program. Any forward-looking statements contained herein
are based on current expectations, and are subject to a number of
risks and uncertainties. Factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
company’s ability to successfully open additional clinical sites
for enrollment and to enroll additional patients; the timing of the
Institutional Review Board process; the company’s ability to
commercialize its products; the company’s ability to develop,
market and sell products based on its technology; the expected
benefits and efficacy of the company’s products and technology in
connection with the treatment of spinal cord injuries; the
availability of substantial additional funding for the company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and other
risks associated with the company’s business, research, product
development, regulatory approval, marketing and distribution plans
and strategies identified and described in more detail in the
company’s Quarterly Report of the three months ended March 31,
2017, and its other filings with the SEC, including the company’s
Form 10-Qs and current reports on Form 8-K. The company does not
undertake to update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170508005337/en/
InVivo TherapeuticsInvestor RelationsHeather
Hamel, 617-863-5530Investor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024